Generation of more effective cancer vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2543-2547

  Fenoglio, Daniela ^a,b   Traverso, Paolo ^a   Parodi, Alessia ^a   Kalli, Francesca ^a   Zanetti, Maurizio ^c   Filaci, Gilberto ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adjuvants; Cancer vaccines; Combinatorial therapy; Telomerase; Tumor antigen; Tumor immune escape

Indexed keywords

CANCER VACCINE; GX 301; IMIQUIMOD; INTERLEUKIN 10 ANTIBODY; IPILIMUMAB; MONTANIDE ISA 51; SIPULEUCEL T; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; NONHUMAN; PERSONALIZED MEDICINE; PROSTATE CANCER; REVIEW; TUMOR ESCAPE; TUMOR REJECTION;

ADJUVANTS; CANCER VACCINES; COMBINATORIAL THERAPY; TELOMERASE; TUMOR ANTIGEN; TUMOR IMMUNE ESCAPE;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84893031843     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26147     Document Type: Review

References (50)

1. Kantoff PW, Higano CS, Shore N.D., Berger ER, Small EJ, Penson DF, Redfern C.H., Ferrari AC, Dreicer R, Sims RB, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22; PMID: 20818862; http://dx.doi.org/10. 1056/NEJMoa1001294
2. Parmiani G, Castelli C, Dalerba P., Mortarini R, Rivoltini L, Marincola F.M., Anichini A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: (Pubitemid 34705052)
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immu-notherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15; PMID: 15340416; http://dx.doi.org/ 10.1038/nm1100 (Pubitemid 39273730)
4. Yang JC. Melanoma vaccines. Cancer J 2011; 17: 277-82; PMID: 21952276; http://dx.doi.org/10.1097/PPO.0b013e3182325f72
5. Therasse P, Arbuck SG, Eisenhauer E.A., Wanders J., Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16; PMID: 10655437; http://dx.doi.org/10.1093/jnci/92.3.205
6. Scher HI, Halabi S, Tannock I., Morris M, Sternberg CN, Carducci M.A., Eisenberger MA, Higano C, Bubley GJ, Dreicer R, et al.; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59; PMID: 18309951; http://dx.doi.org/10.1200/JCO.2007.12. 4487
7. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M., Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20; PMID: 19934295; http://dx.doi.org/10.1158/1078-0432.CCR- 09-1624
8. Cheever MA, Allison JP, Ferris A.S., Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville S.A., Viner JL, Weiner LM, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37; PMID: 19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
9. Parmiani G, Castelli C, Rivoltini L., Casati C, Tully GA, Novellino L, Patuzzo A., Tosi D, Anichini A, Santinami M. Immunotherapy of melanoma. Semin Cancer Biol 2003; 13: 391-400; PMID: 15001157; http://dx.doi.org/10.1016/j. semcancer.2003.09.001 (Pubitemid 38156130)
10. Aly HA. Cancer therapy and vaccination. J Immunol Methods 2012; 382: 1-23; PMID: 22658969; http://dx.doi.org/10.1016/j.jim.2012.05.014
11. Walter S, Weinschenk T, Stenzl A., Zdrojowy R, Pluzanska A, Szczylik C., Staehler M, Brugger W, Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-61; PMID: 22842478; http://dx.doi.org/10.1038/nm.2883
12. Haen SP, Rammensee HG. The repertoire of human tumor-associated epitopes-identification and selection of antigens and their application in clinical trials. Curr Opin Immunol 2013; 25: 277-83; PMID: 23619309; http://dx.doi.org/10.1016/j.coi.2013.03.007
13. Beatty GL, Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008; 7: 881-7; PMID: 18767939; http://dx.doi.org/10.1586/14760584.7.7.881
14. Andersen MH, Svane IM, Becker J.C., Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13: 5991-4; PMID: 17947459; http://dx.doi.org/10.1158/1078-0432.CCR-07-0686 (Pubitemid 350075053)
15. Fenoglio D, Traverso P, Parodi A., Tomasello L, Negrini S, Kalli F., Battaglia F, Ferrera F, Sciallero S., Murdaca G, et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immuno-genic in patients with prostate and renal cancer. Cancer Immunol Immunother 2013; 62: 1041-52; PMID: 23591981; http://dx.doi.org/10.1007/s00262-013-1415-9
16. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen G.L., Gaudernack G., Aamdal S. Telomerase peptide vaccination in NSCLC: A phase II trial in stage III patients vaccinated after chemora-diotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17: 6847-57; PMID: 21918169; http://dx.doi.org/10.1158/1078-0432.CCR-11- 1385
17. Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen A.M., Braathen LR, Gaudernack G. Vaccination of patients with cutaneous melanoma with telomerase-specific peptides. Cancer Immunol Immunother 2011; 60: 1553-64; PMID: 21681371; http://dx.doi.org/10.1007/s00262- 011-1061-z
18. Rittig SM, Haentschel M, Weimer K.J., Heine A., Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A., Hoerr I, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical ben-efit in vaccinated patients. Mol Ther 2011; 19: 990-9; PMID: 21189474; http://dx.doi.org/10.1038/mt.2010.289
19. Berntsen A, Trepiakas R, Wenandy L., Geertsen PF, thor Straten P, Andersen MH, Pedersen A.E., Claesson MH, Lorentzen T, Johansen JS, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1/2 trial. J Immunother 2008; 31: 771-80; PMID: 18779742; http://dx.doi.org/10.1097/CJI.0b013e3181833818
20. Cortez-Gonzalez X., Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007; 5: 12; PMID: 17324292; http://dx.doi.org/10.1186/ 1479-5876-5-12 (Pubitemid 46510393)
21. Su Z, Dannull J, Heiser A., Yancey D, Pruitt S, Madden J., Coleman D, Niedzwiecki D, Gilboa E., Vieweg J. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003; 63: 2127-33; PMID: 12727829 (Pubitemid 36538616)
22. Corbière V., Chapiro J, Stroobant V., Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71: 1253-62; PMID: 21216894; http://dx.doi.org/10. 1158/0008-5472.CAN-10-2693
23. Inderberg-Suso E.M., Trachsel S, Lislerud K., Rasmussen AM, Gaudernack G. Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001. Oncoimmunology 2012; 1: 670-86; PMID: 22934259; http://dx.doi.org/10.4161/onci.20426
24. Rivoltini L, Carrabba M, Huber V., Castelli C, Novellino L, Dalerba P., Mortarini R, Arancia G, Anichini A., Fais S, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97-113; PMID: 12445284; http://dx.doi.org/10.1034/j.1600-065X.2002.18809.x (Pubitemid 35398868)
25. Slingluff CL Jr., Lee S, Zhao F, Chianese-Bullock KA, Olson WC, Butterfield LH, Whiteside TL, Leming PD, Kirkwood JM. A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma (E1602). Clin Cancer Res 2013; In press; http://dx.doi.org/10.1158/1078-0432.CCR-13-0002
26. Yamada A, Sasada T, Noguchi M., Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci 2013; 104: 15-21; PMID: 23107418; http://dx.doi.org/10.1111/cas.12050
27. Phuphanich S, Wheeler CJ, Rudnick J.D., Mazer M., Wang H, Nuño MA, Richardson J.E., Fan X., Ji J, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62: 125-35; PMID: 22847020; http://dx.doi.org/10.1007/s00262-012-1319-0
28. Nunes-Xavier C.E., Martín-Pérez J, Elson A, Pulido R. Protein tyrosine phosphatases as novel targets in breast cancer therapy. Biochim Biophys Acta 2013; 1836: 211-26; PMID: 23756181
29. Disis ML, Wallace DR, Gooley T.A., Dang Y., Slota M, Lu H, Coveler A.L., Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with meta-static breast cancer. J Clin Oncol 2009; 27: 4685-92; PMID: 19720923; http://dx.doi.org/10.1200/JCO.2008.20. 6789
30. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10: 588-94; PMID: 9794842; http://dx.doi.org/10.1016/S0952-7915(98)80228-8 (Pubitemid 28479193)
31. Mumberg D, Monach PA, Wanderling S, Philip M., Toledano AY, Schreiber RD, Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 1999; 96: 8633-8; PMID: 10411927; http://dx.doi.org/10.1073/pnas.96.15.8633 (Pubitemid 29354843)
32. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C., Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357-68; PMID: 9858522; http://dx.doi.org/10.1084/jem.188.12.2357 (Pubitemid 29028508)
33. Ossendorp F, Mengedé E, Camps M, Filius R., Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693-702; PMID: 9480979; http://dx.doi.org/10.1084/jem.187.5.693 (Pubitemid 28115185)
34. Vergati M, Intrivici C, Huen N.Y., Schlom J., Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010: 1; PMID: 20706612; http://dx.doi.org/10.1155/2010/596432
35. Kenter GG, Welters MJ, Valentijn A.R., Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers L.M., Offringa R., Drijfhout J W, et al. Vaccination against HPV-16 oncoproteins for vul-var intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47; PMID: 19890126; http://dx.doi.org/10.1056/ NEJMoa0810097
36. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114-9; PMID: 11154927; http://dx.doi.org/10.1016/S0952- 7915(00)00191-6 (Pubitemid 32096970)
37. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34; PMID: 21235323; http://dx.doi.org/10. 3109/08830185.2010.529976
38. Akira S. Innate immunity and adjuvants. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2748-55; PMID: 21893536; http://dx.doi.org/10.1098/rstb.2011.0106
39. Dubensky TW Jr., Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010; 22: 155-61; PMID: 20488726; http://dx.doi.org/10.1016/j.smim.2010.04.007
40. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30: 150-82; PMID: 21557641; http://dx.doi.org/10.3109/08830185.2011.572210
41. Aucouturier J, Dupuis L, Deville S., Ascarateil S, Ganne V. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1: 111-8; PMID: 12908518; http://dx.doi.org/10.1586/14760584.1.1.111 (Pubitemid 36686885)
42. Schön M.P., Schön M. Imiquimod: mode of action. Br J Dermatol 2007; 157(Suppl 2): 8-13; PMID: 18067624; http://dx.doi.org/10.1111/j.1365-2133. 2007.08265.x (Pubitemid 350179622)
43. Bal SM, Ding Z, van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010; 148: 266-82; PMID: 20869998; http://dx.doi.org/10.1016/j.jconrel.2010.09. 018
44. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33: 464-78; PMID: 21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007
45. Church SE, Jensen SM, Twitty C.G., Bahjat K., Hu HM, Urba WJ, Fox BA. Multiple vaccinations: friend or foe. Cancer J 2011; 17: 379-96; PMID: 21952289; http://dx.doi.org/10.1097/PPO.0b013e3182346320
46. Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013; 00024-9; PMID: 23706598
47. Sharma P, Wagner K, Wolchok J.D., Allison JP. Novel cancer immunotherapy agents with survival ben-efit: recent successes and next steps. Nat Rev Cancer 2011; 11: 805-12; PMID: 22020206; http://dx.doi.org/10.1038/nrc3153
48. Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18: 11-8; PMID: 18308558; http://dx.doi.org/10.1016/j.gde.2007.12.007 (Pubitemid 351694442)
49. Filaci G, Fenoglio D, Fravega M., Ansaldo G, Borgonovo G, Traverso P., Villaggio B, Ferrera A, Kunkl A., Rizzi M, et al. CD8+ CD28-T regulatory lymphocytes inhibiting T cell proliferative and cyto-toxic functions infiltrate human cancers. J Immunol 2007; 179: 4323-34; PMID: 17878327
50. Kalli F, Machiorlatti R, Battaglia F., Parodi A, Conteduca G, Ferrera F., Proietti M, Tardito S, Sanguineti M., Millo E, et al. Comparative analysis of cancer vaccine settings for the selection of an effective protocol in mice. J Transl Med 2013; 11: 120; PMID: 23663506; http://dx.doi.org/10.1186/1479-5876- 11-120